Targeting Bruton's tyrosine kinase in B cell malignancies

Nature Reviews Cancer

Volumn 14, Issue 4, 2014, Pages 219-232

  Hendriks, Rudi W ^a   Yuvaraj, Saravanan ^a   Kil, Laurens P ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BRUTON TYROSINE KINASE; BRUTON TYROSINE KINASE INHIBITOR; CHEMOKINE RECEPTOR; IBRUTINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MYELOID DIFFERENTIATION FACTOR 88; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE; PHOSPHATIDYLINOSITOL 4 PHOSPHATE KINASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE; STAT5 PROTEIN; STROMAL CELL DERIVED FACTOR 1; TRANSCRIPTION FACTOR II;

ACTIN FILAMENT; ADOPTIVE TRANSFER; ALLELE; ANTIGEN BINDING; ANTIGEN PRESENTATION; APOPTOSIS; AUTOPHOSPHORYLATION; B LYMPHOCYTE; BACTEREMIA; BONE MARROW; CELL ADHESION; CELL DIVISION; CELL MEMBRANE; CELL MIGRATION; CELL SURFACE; CELL SURVIVAL; CROSS LINKING; DISEASE COURSE; DISEASE SEVERITY; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; ENZYME REGULATION; ENZYME STRUCTURE; FOLLICULAR DENDRITIC CELL; FOLLICULAR LYMPHOMA; FOLLOW UP; GAIN OF FUNCTION MUTATION; GENE EXPRESSION PROFILING; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC CELL; HUMAN; INTERNALIZATION; LARGE CELL LYMPHOMA; LYMPHOCYTE; LYMPHOCYTOMA; LYMPHOCYTOSIS; MISSENSE MUTATION; MULTIPLE MYELOMA; MYRISTYLATION; NEUTROPENIA; NONHUMAN; OSTEOCLASTOGENESIS; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHENOTYPE; PNEUMONIA; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVIEW; RNA INTERFERENCE; SECOND MESSENGER; SIGNAL TRANSDUCTION; SPLEEN SIZE; SRC HOMOLOGY DOMAIN; THROMBOCYTOPENIA; TUMOR GROWTH; ZINC FINGER MOTIF;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; ENZYME ACTIVATION; HUMANS; LEUKEMIA, B-CELL; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION;

EID: 84897055483     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3702     Document Type: Review

References (167)

1. Vetrie, D. et al. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature 361, 226-233 (1993).
2. Tsukada, S. et al. Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell 72, 279-290 (1993).
3. Hendriks, R. W., Bredius, R. G., Pike-Overzet, K. & Staal, F. J. Biology and novel treatment options for XLA, the most common monogenetic immunodeficiency in man. Expert Opin. Ther. Targets 15, 1003-1021 (2011).
4. Conley, M. E., Parolini, O., Rohrer, J. & Campana, D. X-linked agammaglobulinemia: new approaches to old questions based on the identification of the defective gene. Immunol. Rev. 138, 5-21 (1994).
5. Rawlings, D. J. et al. Mutation of unique region of Bruton's tyrosine kinase in immunodeficient XID mice. Science 261, 358-361 (1993).
6. Thomas, J. D. et al. Colocalization of X-linked agammaglobulinemia and X-linked immunodeficiency genes. Science 261, 355-358 (1993).
7. Aoki, Y., Isselbacher, K. J. & Pillai, S. Bruton tyrosine kinase is tyrosine phosphorylated and activated in pre-B lymphocytes and receptor-ligated B cells. Proc. Natl Acad. Sci. USA 91, 10606-10609 (1994).
8. de Weers, M. et al. B-cell antigen receptor stimulation activates the human Bruton's tyrosine kinase, which is deficient in X-linked agammaglobulinemia. J. Biol. Chem. 269, 23857-23860 (1994).
9. Saouaf, S. J. et al. Temporal differences in the activation of three classes of non-transmembrane protein tyrosine kinases following B-cell antigen receptor surface engagement. Proc. Natl Acad. Sci. USA 91, 9524-9528 (1994).
10. Khan, W. N. et al. Defective B cell development and function in Btk-deficient mice. Immunity 3, 283-299 (1995).
11. Brorson, K. et al. xid affects events leading to B cell cycle entry. J. Immunol. 159, 135-143 (1997).
12. Solvason, N. et al. Transgene expression of bcl-xL permits anti-immunoglobulin (Ig)-induced proliferation in xid B cells. J. Exp. Med. 187, 1081-1091 (1998).
13. Hendriks, R. W. & Middendorp, S. The pre-BCR checkpoint as a cell-Autonomous proliferation switch. Trends Immunol. 25, 249-256 (2004).
14. de Weers, M. et al. The Bruton's tyrosine kinase gene is expressed throughout B cell differentiation, from early precursor B cell stages preceding immunoglobulin gene rearrangement up to mature B cell stages. Eur. J. Immunol. 23, 3109-3114 (1993).
15. Katz, F. E. et al. Expression of the X-linked agammaglobulinemia gene, btk in B-cell acute lymphoblastic leukemia. Leukemia 8, 574-577 (1994).
16. Mahajan, S. et al. Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [α-cyano-β- hydroxy-β-methyl-N-(2, 5-dibromophenyl)propenamide]. J. Biol. Chem. 274, 9587-9599 (1999).
17. Honigberg, L. A. et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc. Natl Acad. Sci. USA 107, 13075-13080 (2010).
18. Davis, R. E. et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 463, 88-92 (2010).
19. Byrd, J. C. et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 369, 32-42 (2013).
20. Wang, M. L. et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N. Engl. J. Med. 369, 507-516 (2013).
21. Smith, C. I. et al. Expression of Bruton's agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells. J. Immunol. 152, 557-565 (1994).
22. Bradshaw, J. M. The Src, Syk, and Tec family kinases: distinct types of molecular switches. Cell Signal 22, 1175-1184 (2010).
23. Hyvonen, M. & Saraste, M. Structure of the PH domain and Btk motif from Bruton's tyrosine kinase: molecular explanations for X-linked agammaglobulinaemia. EMBO J. 16, 3396-3404 (1997).
24. Park, H. et al. Regulation of Btk function by a major autophosphorylation site within the SH3 domain. Immunity 4, 515-525 (1996).
25. Rawlings, D. J. et al. Activation of BTK by a phosphorylation mechanism initiated by SRC family kinases. Science 271, 822-825 (1996).
26. Li, T. et al. Activation of Bruton's tyrosine kinase (BTK) by a point mutation in its pleckstrin homology (PH) domain. Immunity 2, 451-460 (1995).
27. Dingjan, G. M. et al. Severe B cell deficiency and disrupted splenic architecture in transgenic mice expressing the E41K mutated form of Bruton's tyrosine kinase. EMBO J. 17, 5309-5320 (1998).
28. Valiaho, J., Smith, C. I. & Vihinen, M. BTKbase: the mutation database for X-linked agammaglobulinemia. Hum. Mutat. 27, 1209-1217 (2006).
29. Middendorp, S., Dingjan, G. M., Maas, A., Dahlenborg, K. & Hendriks, R. W. Function of Bruton's tyrosine kinase during B cell development is partially independent of its catalytic activity. J. Immunol. 171, 5988-5996 (2003).
30. Gustafsson, M. O. et al. Regulation of nucleocytoplasmic shuttling of Bruton's tyrosine kinase (Btk) through a novel SH3-dependent interaction with ankyrin repeat domain 54 (ANKRD54). Mol. Cell. Biol. 32, 2440-2453 (2012).
31. Hirano, M. et al. Bruton's tyrosine kinase (Btk) enhances transcriptional co-Activation activity of BAM11, a Btk-Associated molecule of a subunit of SWI/SNF complexes. Int. Immunol. 16, 747-757 (2004).
32. Rajaiya, J. et al. Induction of immunoglobulin heavy-chain transcription through the transcription factor Bright requires TFII-I. Mol. Cell. Biol. 26, 4758-4768 (2006).
33. Nisitani, S. et al. Posttranscriptional regulation of Bruton's tyrosine kinase expression in antigen receptor-stimulated splenic B cells. Proc. Natl Acad. Sci. USA 97, 2737-2742 (2000).
34. Belver, L, de Yebenes, V. G. & Ramiro, A. R. MicroRNAs prevent the generation of autoreactive antibodies. Immunity 33, 713-722 (2010).
35. Yu, L. et al. Proteasome-dependent autoregulation of Bruton tyrosine kinase (Btk) promoter via NF-KB. Blood 111, 4617-4626 (2008).
36. Satterthwaite, A. B., Cheroutre, H., Khan, W. N., Sideras, P. & Witte, O. N. Btk dosage determines sensitivity to B cell antigen receptor cross-linking. Proc. Natl Acad. Sci. USA 94, 13152-13157 (1997).
37. Drabek, D. et al. Correction of the X-linked immunodeficiency phenotype by transgenic expression of human Bruton tyrosine kinase under the control of the class II major histocompatibility complex Ea locus control region. Proc. Natl Acad. Sci. USA 94, 610-615 (1997).
38. Kil, L. P. et al. Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice. Blood 119, 3744-3756 (2012).
39. Kil, L. P. et al. Bruton's tyrosine kinase mediated signaling enhances leukemogenesis in a mouse model for chronic lymphocytic leukemia. Am. J. Blood Res. 3, 71-83 (2013).
40. Rolli, V. et al. Amplification of B cell antigen receptor signaling by a Syk/ITAM positive feedback loop. Mol. Cell 10, 1057-1069 (2002).
41. O'Rourke, L. M. et al. CD19 as a membrane-Anchored adaptor protein of B lymphocytes: costimulation of lipid and protein kinases by recruitment of Vav Immunity 8, 635-645 (1998).
42. Inabe, K. et al. Vav3 modulates B cell receptor responses by regulating phosphoinositide 3-kinase activation. J. Exp. Med. 195, 189-200 (2002).
43. Okada, T., Maeda, A., Iwamatsu, A., Gotoh, K. & Kurosaki, T. BCAP: the tyrosine kinase substrate that connects B cell receptor to phosphoinositide 3-kinase activation. Immunity 13, 817-827 (2000).
44. Saito, K., Scharenberg, A. M. & Kinet, J. P. Interaction between the Btk PH domain and phosphatidylinositol-3, 4, 5-trisphosphate directly regulates Btk. J. Biol. Chem. 276, 16201-16206 (2001).
45. Kurosaki, T. & Kurosaki, M. Transphosphorylation of Bruton's tyrosine kinase on tyrosine 551 is critical for B cell antigen receptor function. J. Biol. Chem. 272, 15595-15598 (1997).
46. Fu, C, Turck, C. W., Kurosaki, T & Chan, A. C. BLNK: a central linker protein in B cell activation. Immunity 9, 93-103 (1998).
47. Oellerich, T et al. The B-cell antigen receptor signals through a preformed transducer module of SLP65 and CIN85. EMBO J. 30, 3620-3634 (2011).
48. Weber, M. et al. Phospholipase C-y2 and Vav cooperate within signaling microclusters to propagate B cell spreading in response to membrane-bound antigen. J. Exp. Med. 205, 853-868 (2008).
49. Kim, Y. J., Sekiya, F, Poulin, B., Bae, Y. S. & Rhee, S. G. Mechanism of B-cell receptor-induced phosphorylation and activation of phospholipase C-y2. Mol. Cell. Biol. 24, 9986-9999 (2004).
50. Saito, K. et al. BTK regulates PtdIns-4, 5-P2 synthesis: importance for calcium signaling and PI3K activity. Immunity 19, 669-678 (2003).
51. Hashimoto, A. et al. Involvement of guanosine triphosphatases and phospholipase C-y2 in extracellular signal-regulated kinase, c-Jun NH2-terminal kinase, and p38 mitogen-Activated protein kinase activation by the B cell antigen receptor. J. Exp. Med. 188, 1287-1295 (1998).
52. Shinohara, H., Maeda, S., Watarai, H. & Kurosaki, T IKB kinase p-induced phosphorylation of CARMA1 contributes to CARMA1 Bcl10 MALT1 complex formation in B cells. J. Exp. Med. 204, 3285-3293 (2007).
53. Petro, J. B., Rahman, S. M., Ballard, D. W. & Khan, W. N. Bruton's tyrosine kinase is required for activation of IKB kinase and nuclear factor KB in response to B cell receptor engagement. J. Exp. Med. 191, 1745-1754 (2000).
54. Bajpai, U. D., Zhang, K., Teutsch, M., Sen, R. & Wortis, H. H. Bruton's tyrosine kinase links the B cell receptor to nuclear factor KB activation. J. Exp. Med. 191, 1735-1744 (2000).
55. Sharma, S., Orlowski, G. & Song, W. Btk regulates B cell receptor-mediated antigen processing and presentation by controlling actin cytoskeleton dynamics in B cells. J. Immunol. 182, 329-339 (2009).
56. Nore, B. F et al. Redistribution of Bruton's tyrosine kinase by activation of phosphatidylinositol 3-kinase and Rho-family GTPases. Eur. J. Immunol. 30, 145-154 (2000).
57. Yao, L. et al. Pleckstrin homology domains interact with filamentous actin. J. Biol. Chem. 274, 19752-19761 (1999).
58. Kuehn, H. S. et al. Btk-dependent Rac activation and actin rearrangement following FcsRI aggregation promotes enhanced chemotactic responses of mast cells. J. Cell Sci. 123, 2576-2585 (2010).
59. Spaargaren, M. et al. The B cell antigen receptor controls integrin activity through Btk and PLCy2. J. Exp. Med. 198, 1539-1550 (2003).
60. Koopman, G. et al. Adhesion through the LFA-1 (CD1 1a/CD18)-ICAM-1 (CD54) and the VLA-4 (CD49d)-VCAM-1 (CD106) pathways prevents apoptosis of germinal center B cells. J. Immunol. 152, 3760-3767 (1994).
61. Guo, B., Kato, R. M., Garcia-Lloret, M., Wahl, M. I. & Rawlings, D. J. Engagement of the human pre-B cell receptor generates a lipid raft-dependent calcium signaling complex. Immunity 13, 243-253 (2000).
62. Pede, V. et al. Expression of ZAP70 in chronic lymphocytic leukaemia activates NF-KB signalling. Br J. Haematol. 163, 621-630 (2013).
63. Ubelhart, R. et al. N-linked glycosylation selectively regulates autonomous precursor BCR function. Nature Immunol. 11, 759-765 (2010).
64. Gauthier, L., Rossi, B., Roux, F, Termine, E. & Schiff, C. Galectin-1 is a stromal cell ligand of the pre-B cell receptor (BCR) implicated in synapse formation between pre-B and stromal cells and in pre-BCR triggering. Proc. Natl Acad. Sci. USA 99, 13014-13019 (2002).
65. Bradl, H., Wittmann, J., Milius, D., Vettermann, C. & Jack, H. M. Interaction of murine precursor B cell receptor with stroma cells is controlled by the unique tail of A. 5 and stroma cell-Associated heparan sulfate. J. Immunol. 171, 2338-2348 (2003).
66. Flemming, A., Brummer, T, Reth, M. & Jumaa, H. The adaptor protein SLP-65 acts as a tumor suppressor that limits pre-B cell expansion. Nature Immunol. 4, 38-43 (2003).
67. van Loo, P. F, Dingjan, G. M., Maas, A. & Hendriks, R. W. Surrogate-light-chain silencing is not critical for the limitation of pre-B cell expansion but is for the termination of constitutive signaling. Immunity 27, 468-480 (2007).
68. Nakayama, J. et al. BLNK suppresses pre-B-cell leukemogenesis through inhibition of JAK3. Blood 113, 1483-1492 (2009).
69. Kersseboom, R. et al. Bruton's tyrosine kinase cooperates with the B cell linker protein SLP-65 as a tumor suppressor in Pre-B cells. J. Exp. Med. 198, 91-98 (2003).
70. Middendorp, S. et al. Tumor suppressor function of Bruton tyrosine kinase is independent of its catalytic activity. Blood 105, 259-265 (2005).
71. Jumaa, H. et al. Deficiency of the adaptor SLP-65 in pre-B-cell acute lymphoblastic leukaemia. Nature 423, 452-456 (2003).
72. Goodman, P. A., Wood, C. M., Vassilev, A. O., Mao, C. & Uckun, F. M. Defective expression of Bruton's tyrosine kinase in acute lymphoblastic leukemia. Leuk. Lymphoma 44, 1011-1018 (2003).
73. Feldhahn, N. et al. Deficiency of Bruton's tyrosine kinase in B cell precursor leukemia cells. Proc. Natl Acad. Sci. USA 102, 13266-13271 (2005).
74. de Gorter, D. J. et al. Bruton's tyrosine kinase and phospholipase Cγ2 mediate chemokine-controlled B cell migration and homing. Immunity 26, 93-104 (2007).
75. Tsukada, S., Simon, M. I., Witte, O. N. & Katz, A. Binding of βγ subunits of heterotrimeric G proteins to the PH domain of Bruton tyrosine kinase. Proc. Natl Acad. Sci. USA 91, 11256-11260 (1994).
76. Jiang, Y. et al. The G protein G α12 stimulates Bruton's tyrosine kinase and a rasGAP through a conserved PH/BM domain. Nature 395, 808-813 (1998).
77. Lowry, W. E. & Huang, X. Y. G. Protein βγ subunits act on the catalytic domain to stimulate Bruton's agammaglobulinemia tyrosine kinase. J. Biol. Chem. 277, 1488-1492 (2002).
78. de Rooij, M. F. et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor-And chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood 119, 2590-2594 (2012).
79. + cells into peripheral blood following treatment with the BTK inhibitor ibrutinib in mantle cell lymphoma patients. Blood 122, 2412-2424 (2013).
80. Ponader, S. et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 119, 1182-1189 (2012).
81. Rawlings, D. J., Schwartz, M. A., Jackson, S. W. & Meyer-Bahlburg, A. Integration of B cell responses through Toll-like receptors and antigen receptors. Nature Rev. Immunol. 12, 282-294 (2012).
82. Jefferies, C. A. et al. Bruton's tyrosine kinase is a Toll/interleukin-1 receptor domain-binding protein that participates in nuclear factor κB activation by Toll-like receptor 4. J. Biol. Chem. 278, 26258-26264 (2003).
83. Liu, X. et al. Intracellular MHC class II molecules promote TLR-triggered innate immune responses by maintaining activation of the kinase Btk. Nature Immunol. 12, 416-424 (2011).
84. Lee, K. G. et al. Bruton's tyrosine kinase phosphorylates Toll-like receptor 3 to initiate antiviral response. Proc. Natl Acad. Sci. USA 109, 5791-5796 (2012).
85. Marron, T. U., Martinez-Gallo, M., Yu, J. E. & Cunningham-Rundles, C. Toll-like receptor 4-, 7-, and 8-Activated myeloid cells from patients with X-linked agammaglobulinemia produce enhanced inflammatory cytokines. J. Allergy Clin. Immunol. 129, 184-190 (2012).
86. Kenny, E. F. et al. Bruton's tyrosine kinase mediates the synergistic signalling between TLR9 and the B cell receptor by regulating calcium and calmodulin. PLoS ONE 8, e74103 (2013).
87. Chaturvedi, A., Dorward, D. & Pierce, S. K. The B cell receptor governs the subcellular location of Toll-like receptor 9 leading to hyperresponses to DNA-containing antigens. Immunity 28, 799-809 (2008).
88. Muzio, M. et al. Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy. Blood 112, 188-195 (2008).
89. Mockridge, C. I. et al. Reversible anergy of sIgM-mediated signaling in the two subsets of CLL defined by VH-gene mutational status. Blood 109, 4424-4431 (2007).
90. Herishanu, Y. et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 117, 563-574 (2011).
91. Hoogeboom, R. et al. A mutated B cell chronic lymphocytic leukemia subset that recognizes and responds to fungi. J. Exp. Med. 210, 59-70 (2013).
92. Kil, L. P., Yuvaraj, S., Langerak, A. W. & Hendriks, R. W. The role of B cell receptor stimulation in CLL pathogenesis. Curr. Pharm. Des. 18, 3335-3355 (2012).
93. Duhren-von Minden, M. et al. Chronic lymphocytic leukaemia is driven by antigen-independent cell-Autonomous signalling. Nature 489, 309-312 (2012).
94. Herman, S. E. et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 117, 6287-6296 (2011).
95. ter Brugge, P. J. et al. A mouse model for chronic lymphocytic leukemia based on expression of the SV40 large T antigen. Blood 114, 119-127 (2009).
96. Dubovsky, J. A. et al. Lymphocyte cytosolic protein 1 is a chronic lymphocytic leukemia membrane-Associated antigen critical to niche homing. Blood 122, 3308-3316 (2013).
97. Hoogeboom, R. et al. A novel chronic lymphocytic leukemia subset expressing mutated IGHV3-7-encoded rheumatoid factor B-cell receptors that are functionally proficient. Leukemia 27, 738-740 (2013).
98. Sivina, M. et al. CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemia. Blood 117, 1662-1669 (2011).
99. Hadzidimitriou, A. et al. Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases. Blood 118, 3088-3095 (2011).
100. Pighi, C. et al. Phospho-proteomic analysis of mantle cell lymphoma cells suggests a pro-survival role of B-cell receptor signaling. Cell Oncol. 34, 141-153 (2011).
101. Boyd, R. S. et al. Protein profiling of plasma membranes defines aberrant signaling pathways in mantle cell lymphoma. Mol. Cell Proteomics. 8, 1501-1515 (2009).
102. Rinaldi, A. et al. Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma. Br. J. Haematol. 132, 303-316 (2006).
103. Jares, P., Colomer, D. & Campo, E. Molecular pathogenesis of mantle cell lymphoma. J. Clin. Invest. 122, 3416-3423 (2012).
104. Cinar, M. et al. Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis. Leuk. Res. 37, 1271-1277 (2013).
105. Alizadeh, A. A. et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403, 503-511 (2000).
106. Davis, R. E., Brown, K. D., Siebenlist, U. & Staudt, L. M. Constitutive nuclear factor κB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J. Exp. Med. 194, 1861-1874 (2001).
107. Ngo, V. N. et al. A loss-of-function RNA interference screen for molecular targets in cancer. Nature 441, 106-110 (2006).
108. Lenz, G. et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 319, 1676-1679 (2008).
109. Compagno, M. et al. Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma. Nature 459, 717-721 (2009).
110. Ngo, V. N. et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 470, 115-119 (2011).
111. Monti, S. et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 105, 1851-1861 (2005).
112. Chen, L. et al. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood 111, 2230-2237 (2008).
113. Juszczynski, P. et al. BCL6 modulates tonic BCR signaling in diffuse large B-cell lymphomas by repressing the SYK phosphatase, PTPROt. Blood 114, 5315-5321 (2009).
114. Zhang, J. et al. Genetic heterogeneity of diffuse large B-cell lymphoma. Proc. Natl Acad. Sci. USA 110, 1398-1403 (2013).
115. Chen, L. et al. SYK inhibition modulates distinct PI3K/AKT-dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas. Cancer Cell 23, 826-838 (2013).
116. Hantschel, O. et al. The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc. Natl Acad. Sci. USA 104, 13283-13288 (2007).
117. Treon, S. P. et al. MYD88 L265P somatic mutation in Waldenstrom's macroglobulinemia. N. Engl. J. Med. 367, 826-833 (2012).
118. Yang, G. et al. A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstrom macroglobulinemia. Blood 122, 1222-1232 (2013).
119. Chng, W. J. et al. Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma. Blood 108, 2755-2763 (2006).
120. Ngo, H. T. et al. SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenstrom macroglobulinemia. Blood 112, 150-158 (2008).
121. Kuehl, W. M. & Bergsagel, P. L. Molecular pathogenesis of multiple myeloma and its premalignant precursor. J. Clin. Invest. 122, 3456-3463 (2012).
122. Raje, N. & Roodman, G. D. Advances in the biology and treatment of bone disease in multiple myeloma. Clin. Cancer Res. 17, 1278-1286 (2011).
123. Abe, M. et al. BAFF and APRIL as osteoclast-derived survival factors for myeloma cells: a rationale for TACI-Fc treatment in patients with multiple myeloma. Leukemia 20, 1313-1315 (2006).
124. Alsayed, Y. et al. Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood 109, 2708-2717 (2007).
125. Hideshima, T., Mitsiades, C., Tonon, G., Richardson, P. G. & Anderson, K. C. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nature Rev. Cancer 7, 585-598 (2007).
126. Shinohara, M. et al. Tyrosine kinases Btk and Te c regulate osteoclast differentiation by linking RANK and ITAM signals. Cell 132, 794-806 (2008).
127. Lee, S. H., Kim, T., Jeong, D., Kim, N. & Choi, Y. The tec family tyrosine kinase Btk Regulates RANKL-induced osteoclast maturation. J. Biol. Chem. 283, 11526-11534 (2008).
128. Tai, Y. T. et al. Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood 120, 1877-1887 (2012).
129. Bao, H. et al. Triggering of toll-like receptor-4 in human multiple myeloma cells promotes proliferation and alters cell responses to immune and chemotherapy drug attack. Cancer Biol. Ther. 11, 58-67 (2011).
130. Chapman, M. A. et al. Initial genome sequencing and analysis of multiple myeloma. Nature 471, 467-472 (2011).
131. Keats, J. J. et al. Promiscuous mutations activate the noncanonical NF-κB pathway in multiple myeloma. Cancer Cell 12, 131-144 (2007).
132. Annunziata, C. M. et al. Frequent engagement of the classical and alternative NF-κB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12, 115-130 (2007).
133. Advani, R. H. et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J. Clin. Oncol. 31, 88-94 (2013).
134. O'Brien, S. et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol. 15, 48-58 (2014).
135. Woyach, J. A. et al. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood http://dx.doi.org/10.1182/blood-2013-09- 527853 (2014).
136. Burger, J. A., Wierda, W. G. & Hoellenriegel, J. The Btk inhibitor ibrutinib (PCI-32765) in combination with rituximab is well tolerated and displays profound activity in high-risk chronic lymphocytic leukemia (CLL) patients. Proc ASH Abstr.187 (2012).
137. Brown, J. R. Combination of the Bruton's tyrosine kinase inhibitor PCI-32765 with bendamustine/rituximab (BR) in patients with relapsed/refractory chronic lymphocytic leukemia: Interim results of a phase Ib/II study. EHA Meeting 2012 Abstr.1590 (2012).
138. Chang, B. Y. et al. Use of tumor genomic profiling to reveal mechanisms of resistance to the BTK inhibitor ibrutinib in chronic lymphocytic leukemia (CLL). J Clin. Oncol. 31 428S (2013).
139. Rahal, R. et al. Pharmacological and genomic profiling identifies NF-κB-targeted treatment strategies for mantle cell lymphoma. Nature Med. 20, 87-92 (2014).
140. Wilson, W., Gerecitano, J., Goy, A. & De Vos, S. The bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the abc subtype of relapsed/refractory de novo diffuse large b-cell lymphoma (DLBCL): interim results of a multicenter, open-label, phase 2 study. Proc ASH Abstr. 686 (2012).
141. Treon, S. P. A prospective, multicenter, phase II study of the Bruton's tyrosine kinase inhibitor ibrutinib in patients with relapsed and refractory Waldenstrom's macroglobulinemia. ICML Abstr. 067 (2013).
142. Vij, R., Chang, B., Berdeja, J. & Huff, C. Early changes in cytokines, chemokines and indices of bone metabolism in a phase 2 study of the bruton tyrosine kinase (Btk) inhibitor, ibrutinib (PCI-32765) in patients with relapsed or relapsed/refractory multiple myeloma (MM). Proc ASH Abstr.4039 (2012).
143. Yan, Q. et al. BCR and TLR signaling pathways are recurrently targeted by genetic changes in splenic marginal zone lymphomas. Haematologica 97, 595-598 (2012).
144. Sachen, K. L. et al. Self-Antigen recognition by follicular lymphoma B-cell receptors. Blood 120, 4182-4190 (2012).
145. Dias, C. & Isenberg, D. A. Susceptibility of patients with rheumatic diseases to B-cell non-Hodgkin lymphoma. Nature Rev. Rheumatol. 7, 360-368 (2011).
146. Di Paolo, J. A. et al. Specific Btk inhibition suppresses B cell-And myeloid cell-mediated arthritis. Nature Chem. Biol. 7, 41-50 (2011).
147. Liu, L. et al. Antiarthritis effect of a novel Bruton's tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy. J. Pharmacol. Exp. Ther. 338, 154-163 (2011).
148. Mina-Osorio, P. et al. Suppression of glomerulonephritis in lupus-prone NZB x NZW mice by RN486, a selective inhibitor of Bruton's tyrosine Kinase. Arthritis Rheum. 65, 2380-2391 (2013).
149. Rankin, A. L. et al. Selective inhibition of BTK prevents murine lupus and antibody-mediated glomerulonephritis. J. Immunol. 191, 4540-4550 (2013).
150. Eifert, C. et al. A novel isoform of the B cell tyrosine kinase BTK protects breast cancer cells from apoptosis. Genes Chromosomes Cancer 52, 961-975 (2013).
151. Mathews Griner, L. A. et al. High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells. Proc. Natl Acad. Sci. USA 111, 2349-2354 (2014).
152. Winkelstein, J. A. et al. X-linked agammaglobulinemia: report on a United States registry of 201 patients. Medicine 85, 193-202 (2006).
153. Nomura, K. et al. Genetic defect in human X-linked agammaglobulinemia impedes a maturational evolution of pro-B cells into a later stage of pre-B cells in the B-cell differentiation pathway. Blood 96, 610-617 (2000).
154. Ng, Y. S., Wardemann, H., Chelnis, J., Cunningham-Rundles, C. & Meffre, E. Bruton's tyrosine kinase is essential for human B cell tolerance. J. Exp. Med. 200, 927-934 (2004).
155. Hendriks, R. W. et al. Inactivation of Btk by insertion of lacZ reveals defects in B cell development only past the pre-B cell stage. EMBO J. 15, 4862-4872 (1996).
156. Middendorp, S., Dingjan, G. M. & Hendriks, R. W. Impaired precursor B cell differentiation in Bruton's tyrosine kinase-deficient mice. J. Immunol. 168, 2695-2703 (2002).
157. Boucheron, N. & Ellmeier, W. The role of Te c family kinases in the regulation of T-helper-cell differentiation. Int. Rev. Immunol. 31, 133-154 (2012).
158. Huck, K. et al. Girls homozygous for an IL-2-inducible T cell kinase mutation that leads to protein deficiency develop fatal EBV-Associated lymphoproliferation. J. Clin. Invest. 119, 1350-1358 (2009).
159. Ellmeier, W. et al. Severe B cell deficiency in mice lacking the tec kinase family members Te c and Btk. J. Exp. Med. 192, 1611-1624 (2000).
160. Cenni, B., Gutmann, S. & Gottar-Guillier, M. BMX and its role in inflammation, cardiovascular disease, and cancer. Int. Rev. Immunol. 31, 166-173 (2012).
161. He, Y. et al. Critical function of Bmx/Etk in ischemia-mediated arteriogenesis and angiogenesis. J. Clin. Invest. 116, 2344-2355 (2006).
162. Dubovsky, J. A. et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a TH1 selective pressure in T-lymphocytes. Blood 122, 2539-2549 (2013).
163. Evans, E. K. et al. Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans. J. Pharmacol. Exp. Ther. 346, 219-228 (2013).
164. Xu, D. et al. RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents. J. Pharmacol. Exp. Ther. 341, 90-103 (2012).
165. Liu, L. et al. Significant species difference in amide hydrolysis of GDC-0834, a novel potent and selective Bruton's tyrosine kinase inhibitor. Drug Metab. Dispos. 39, 1840-1849 (2011).
166. Yoshizawa, T. Development of a Bruton's tyrosine kinase (Btk) inhibitor, ONO-4059: efficacy in a collagen induced arthritis (CIA) model. indicates potential treatment for rheumatoid arthritis (RA). Arthritis Rheum. 64 (Suppl. 10), 1660 (2012).
167. Labenski, M. T. et al. In vitroreactivity assessment of covalent drugs targeting Bruton's tyrosine kinase. 17th North Am. Meet. Int. Soc. Study Xenobiot. (ISSX) Abst. P 211 (2011).